Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Moderate-to-Severe Atopic Dermatitis
NCT05186922Phase 2Unknown
- Sponsor
- Keymed Biosciences
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CM326 in atopic dermatitis (AD), sponsored by Keymed Biosciences. Status: unknown.
02
Drugs
CM326
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05186922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186922.